Form 6K Biontech Se For: 18 December
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioNTech SE (BNTX)
Get information about the BioNTech Stock. Find more details on BNTX stock price to help you take informed decisions by going to one of the sections under this page - from BNTX Stock historical data, price charts and technical analysis to the balance sheet. Find BioNTech quotes in the main stock markets such as NASDAQ and Frankfurt, among others.
95.06
-0.14(-0.15%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
94.55
95.40
52 wk Range
81.20
129.27
BNTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
94.5595.40
52 wk Range
81.20129.27
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BNTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
139.08
Upside
+46.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
8 analysts have revised their earnings upwards for the upcoming period
- Form 6K Biontech Se For: 9 December
- Investing.com
- Form 6K Biontech Se For: 18 December
- Investing.com
- Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
BioNTech SE Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE SWOT Analysis
Oncology Ambitions | BioNTech aims for 10 new approvals by 2030, with promising results in lung and breast cancer trials showcasing its ambitious oncology pipeline |
Financial Fortitude | $18 billion cash reserves and positive cash flow provide BioNTech with stability and flexibility for R&D investments and strategic acquisitions |
Vaccine Legacy | COVID-19 vaccine business continues to generate substantial revenue, funding BioNTech's transition into a diversified biotechnology powerhouse |
Market Outlook | Analysts set price targets ranging from $125 to $130, reflecting cautious optimism about BioNTech's oncology potential and financial health |
BioNTech SE Earnings Call Summary for Q4/2024
- BioNTech's Q4 EPS of $1.08 and revenue of $1.19B beat forecasts, yet stock fell 2.88% pre-market
- 2024 net loss of €665M, down from €930M profit in 2023; total revenue fell to €2.8B from €3.8B
- 2025 revenue projected at €1.7-2.2B; R&D expenses expected to be €2.6-2.8B
- Focus on oncology expansion, with multiple clinical data updates and potential regulatory submissions planned
- Strong cash position of €17.4B, but high R&D costs and negative EPS forecasts raise profitability concerns
Last Updated: 2025-03-10, 09:38 a/m
Read Full TranscriptCompare BNTX to Peers and Sector
Metrics to compare | BNTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −34.0x | −1.2x | −0.6x | |
PEG Ratio | 1.49 | −0.03 | 0.00 | |
Price/Book | 1.1x | 1.3x | 2.6x | |
Price / LTM Sales | 6.2x | 5.1x | 3.2x | |
Upside (Analyst Target) | 48.9% | 21.6% | 42.7% | |
Fair Value Upside | Unlock | 18.2% | 6.4% | Unlock |
Analyst Ratings
15 Buy
5 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 139.08
(+46.30% Upside)
Earnings
Latest Release
Nov 03, 2025
EPS / Forecast
-0.12 / 0.10
Revenue / Forecast
1.52B / 1.01B
People Also Watch
FAQ
What Is the BioNTech (BNTX) Stock Price Today?
The BioNTech stock price today is 95.06
What Stock Exchange Does BioNTech Trade On?
BioNTech is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for BioNTech?
The stock symbol for BioNTech is "BNTX."
What Is the BioNTech Market Cap?
As of today, BioNTech market cap is 22.82B.
What Is BioNTech's Earnings Per Share (TTM)?
The BioNTech EPS (TTM) is -2.38.
When Is the Next BioNTech Earnings Date?
BioNTech will release its next earnings report on Mar 10, 2026.
From a Technical Analysis Perspective, Is BNTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has BioNTech Stock Split?
BioNTech has split 0 times.
How Many Employees Does BioNTech Have?
BioNTech has 6772 employees.
What is the current trading status of BioNTech (BNTX)?
As of Dec 30, 2025, BioNTech (BNTX) is trading at a price of 95.06, with a previous close of 95.20. The stock has fluctuated within a day range of 94.55 to 95.40, while its 52-week range spans from 81.20 to 129.27.
What Is BioNTech (BNTX) Price Target According to Analysts?
The average 12-month price target for BioNTech is USD139.07741138, with a high estimate of USD175.22906607 and a low estimate of USD102.60275586. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +46.30% Upside potential.
What Is the BNTX Premarket Price?
BNTX's last pre-market stock price is 95.17. The pre-market share volume is 4,690.00, and the stock has decreased by -0.03, or -0.03%.
What Is the BNTX After Hours Price?
BNTX's last after hours stock price is 95.13, the stock has decreased by -0.07, or -0.07%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.